← All trials
NCT06871046
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 20, 2025
- Primary completion
- Sep 22, 2025
- Completion date
- Oct 1, 2025
- First posted
- Mar 11, 2025
- Last posted
- Oct 24, 2025
- Enrollment
- 221
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Teikoku Seiyaku Co., Ltd.Lead sponsor
- ClinSearch, LLCCollaborator
- CRM Biometrics GmbHCollaborator
- SocraTec R&D GmbHCollaborator
- Teikoku Seiyaku Co., Ltd.Official
- SocraMetrics GmbHCollaborator
- HWI pharma services GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.